Use of lactooligosaccharides in preparation of drugs or foods for treating or preventing NEC by alleviating intestinal hypoxia injury

A technology of oligosaccharides and milk sources, which can be used in the field of medicine or food for the treatment or prevention of NEC, milk-derived oligosaccharides, and can solve problems such as incomplete clarity

Inactive Publication Date: 2019-08-16
CHINA AGRI UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Exactly which or which components of breast milk protect the gut and reduce the risk of NEC in breastfed infants is not fully understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of lactooligosaccharides in preparation of drugs or foods for treating or preventing NEC by alleviating intestinal hypoxia injury
  • Use of lactooligosaccharides in preparation of drugs or foods for treating or preventing NEC by alleviating intestinal hypoxia injury
  • Use of lactooligosaccharides in preparation of drugs or foods for treating or preventing NEC by alleviating intestinal hypoxia injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1-Establishment of hypoxia injury model of intestinal cells

[0045] Cell line:

[0046] Caco-2, human colorectal adenocarcinoma cells; IEC-6, rat small intestinal crypt epithelial cells, were purchased from the Cell Bank of the Chinese Academy of Sciences. The cells are all DMEM high glucose complete medium at 37℃, containing 5% CO 2 Culture in the cell incubator.

[0047] Cell processing:

[0048] 2×10 4 The concentration of pieces / mL was inoculated into 96-well plates and cultured for 24h. Then replace with 200 μM CoCl 2 Medium, 100μL per well, another control group and a physical hypoxia treatment group (no CoCl added to the medium 2 Solution, add the same volume of PBS), each treatment group set 6 parallel. The control group and the chemical hypoxia treatment group were placed in an incubator, and the physical hypoxia treatment group was treated as described above and placed in an incubator for different periods of time.

[0049] The effect of different hypoxia me...

Embodiment 2

[0069] Example 2-The mitigation effect of milk-derived oligosaccharides on intestinal cell hypoxia damage

[0070] Taking acid milk-derived oligosaccharides as the research object, eight milk-derived oligosaccharides were selected (see Image 6 , Respectively are: neutral oligosaccharide lactoyl-N-tetraose (LNT); carbon chain backbone is lactose, 3'-sialyllactose (3'-SL), 6'-sialic acid residue carrying a single sialic acid residue Acid lactose (6'-SL); carbon chain backbone is LNT or LNnT, sialic acid-lactyl-N-tetraose a (LSTa), sialic acid-lactyl-N-tetraose with a single sialic acid residue b(LSTb), sialic acid-lactoyl-N-tetraose c (LSTc); carbon chain backbone is LNT, disialyl-lactoyl-N-tetraose (DSLNT) carrying two sialic acid residues; and as In contrast, the carbon chain backbone is lactose, which carries a fucosyl 2'-fucose lactose (2'-FL). The aim is to study the difference of milk-derived oligosaccharides with different carbon chain skeletons and the number of sialic ac...

Embodiment 3

[0089] Example 3-The alleviating effect of milk-derived oligosaccharides on necrotizing enterocolitis in mice

[0090] Experimental animals used in this example: 60 SPF seven-day-old C57BL / 6 mice (male and female) were purchased from Beijing Weitong Lihua Experimental Animal Co., Ltd. The formula design of rat milk substitute for feeding mice is shown in Table 1.

[0091] Table 1 Mouse milk substitute formula design

[0092]

[0093] 100mL mouse milk substitute: 10g Nestlé formula milk powder + 7g protein powder + 47.5mL 20% medium and long chain fatty acid milk + 2.6g lactose, dilute to 100mL, after dissolving in warm water bath, store at 4°C.

[0094] Mouse milk replacer containing 4mg / mL 2’-FL: Dissolve 120mg of 2’-FL in 30mL mouse milk replacer, store at 4°C after mixing, and heat with warm water before each use.

[0095] Mouse milk replacer containing 2mg / mL 3'-SL+6'-SL: Add 600μL of 100mg / mL 3’-SL+6’-SL mixed solution to 29.4mL of mouse milk replacer, and store at 4℃ after mixing...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a use of lactooligosaccharides in preparation of drugs or foods for treating or preventing NEC by alleviating intestinal hypoxia injury. The lactooligosaccharides include fourlactooligosaccharides: 3'-lactose sialate (3'-SL) and 6'-lactose sialate (6'-SL) taking lactose as a carbon chain skeleton and carrying a single sialic acid residue, and sialyl-lactyl-N-tetraose b (LSTb) and sialyl-lactyl-N-tetraose c (LSTc) taking LNT or LNnT as a carbon chain skeleton and carrying a single sialic acid residue. 3'-SL, 6'-SL, LSTb and LSTc are confirmed to be able to significantlyrestore the proliferation ability of Caco-2 cells under hypoxia treatment; 3'-SL and 6'-SL can significantly inhibit the up-regulation of HIF-1[alpha], p-P65 and IL-8 mRNA in the Caco-2 cells under hypoxia treatment.

Description

Technical field [0001] The present invention belongs to the field of food biotechnology, and particularly relates to the use of milk-derived oligosaccharides in the preparation of drugs or foods for treating or preventing NEC by alleviating intestinal hypoxic damage. Background technique [0002] Necrotizing enterocolitis (NEC) is a disease with high mortality rate common in premature infants, with a mortality rate between 10% and 50%. At present, the treatment methods for NEC are very limited. In the early stage, antibiotic therapy is usually used for relief. In the late stage, it can only be treated through surgery. However, postoperative complications of the nervous system and digestive system are often accompanied, which seriously affects the growth and development of the baby. Therefore, prevention of the possible risks caused by NEC is an ideal prevention method. [0003] Current research believes that NEC has two major pathogenesis mechanisms. One is the body damage...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7016A61K31/702A61P1/00A23C9/13A23C9/156A23C9/16A23C19/09A23L2/38A23L19/20A23L33/125
CPCA61K31/7016A61K31/702A61P1/00A23L33/125A23L2/382A23L19/20A23C9/1307A23C9/16A23C9/156A23C19/0925A23V2002/00A23V2200/32A23V2250/612A23V2250/28A61K2300/00
Inventor 郭慧媛任发政李依璇李一然王辰元
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap